Imperial College London
Alternate

Professor Toby Prevost

Faculty of Medicine, School of Public Health

Visiting Professor
 
 
 
//

Contact

 

a.prevost

 
 
//

Location

 

57Stadium HouseWhite City Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Marteau:2012:10.1371/journal.pone.0035249,
author = {Marteau, TM and Aveyard, P and Munafo, MR and Prevost, AT and Hollands, GJ and Armstrong, D and Sutton, S and Hill, C and Johnstone, E and Kinmonth, AL},
doi = {10.1371/journal.pone.0035249},
journal = {PLoS ONE},
pages = {1--9},
title = {Effect on adherence to nicotine replacement therapy of informing smokers their dose is determined by their genotype: a randomised controlled trial},
url = {http://dx.doi.org/10.1371/journal.pone.0035249},
volume = {7},
year = {2012}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - BackgroundThe behavioural impact of pharmacogenomics is untested. We tested two hypotheses concerning the behavioural impact of informing smokers their oral dose of NRT is tailored to analysis of DNA.Methods and FindingsWe conducted an RCT with smokers in smoking cessation clinics (N=633). In combination with NRT patch, participants were informed that their doses of oral NRT were based either on their mu-opioid receptor (OPRM1) genotype, or their nicotine dependence questionnaire score (phenotype). The proportion of prescribed NRT consumed in the first 28 days following quitting was not significantly different between groups: (68.5% of prescribed NRT consumed in genotype vs 63.6%, phenotype group, difference = 5.0%, 95% CI −0.9,10.8, p = 0.098). Motivation to make another quit attempt among those (n = 331) not abstinent at six months was not significantly different between groups (p = 0.23). Abstinence at 28 days was not different between groups (p=0.67); at six months was greater in genotype than phenotype group (13.7% vs 7.9%, difference = 5.8%, 95% CI 1.0,10.7, p = 0.018).ConclusionsInforming smokers their oral dose of NRT was tailored to genotype not phenotype had a small, statistically non-significant effect on 28-day adherence to NRT. Among those still smoking at six months, there was no evidence that saying NRT was tailored to genotype adversely affected motivation to make another quit attempt. Higher abstinence rate at six months in the genotype arm requires investigation.
AU  - Marteau,TM
AU  - Aveyard,P
AU  - Munafo,MR
AU  - Prevost,AT
AU  - Hollands,GJ
AU  - Armstrong,D
AU  - Sutton,S
AU  - Hill,C
AU  - Johnstone,E
AU  - Kinmonth,AL
DO  - 10.1371/journal.pone.0035249
EP  - 9
PY  - 2012///
SN  - 1932-6203
SP  - 1
TI  - Effect on adherence to nicotine replacement therapy of informing smokers their dose is determined by their genotype: a randomised controlled trial
T2  - PLoS ONE
UR  - http://dx.doi.org/10.1371/journal.pone.0035249
UR  - http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000305336600096&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202
UR  - https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0035249
UR  - http://hdl.handle.net/10044/1/72550
VL  - 7
ER  -
Download